Publication date: Nov 20, 2024
The reduction due to KatG mutation resists INH medications commonly used to treat TB and is the most common cause of multi-drug resistance of TB. It will make INH, a common medication used against TB, continuously a more effective treatment that will save millions of lives each year. Research has indicated that Mtb is capable of existing outside of the body for weeks. This is a utility enzyme, and it has never been considered as a drug target. What if we inhibit KatGs catalase activity? KatG serves two functions. KatG has been utilized as a pro-drug activator for more than 72 years.
| Concepts | Keywords |
|---|---|
| Biochemist | Activity |
| Investigator | Catalase |
| Tuberculosis | Diseases |
| University | Drug |
| Weeks | Existing |
| Host | |
| Infectious | |
| Katg | |
| Liu | |
| Mtb | |
| Peroxidase | |
| Project | |
| Team | |
| Utsa | |
| Years |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Oxygen |
| drug | DRUGBANK | Hydrogen peroxide |
| drug | DRUGBANK | Isoniazid |
| pathway | KEGG | Tuberculosis |
| disease | MESH | tuberculosis |
| disease | MESH | infectious diseases |
| disease | IDO | pathogen |
| disease | IDO | host |
| disease | IDO | role |
| drug | DRUGBANK | Ranitidine |
| disease | IDO | facility |
| disease | IDO | protein |